

## Abacavir Oral Solution

<b>Type of Posting</b>	Revision Bulletin
<b>Posting Date</b>	25-Feb-2022
<b>Official Date</b>	1-Mar-2022
<b>Expert Committee</b>	Small Molecules 1

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 1 Expert Committee has revised the Abacavir Oral Solution monograph. The purpose of this revision is to widen the *pH* acceptance criteria from 3.8–4.5 to 3.8–4.8 to accommodate FDA-approved drug products with different limits.

The Abacavir Oral Solution Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Claire Chisolm, Senior Scientist II (301-230-3215 or [cnc@usp.org](mailto:cnc@usp.org)).